ADC Therapeutics SA Cash Flows From Used In Operations Before Changes In Working Capital
ADC Therapeutics SA (ADCT) reported Cash Flows From Used In Operations Before Changes In Working Capital of -$113.28 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes
ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital · last filed 2023-11-07
- ADC Therapeutics SA cash flows from used in operations before changes in working capital for the quarter ending 2023-09-30 was -$33.50M, a 345.05% decline year-over-year.
- ADC Therapeutics SA cash flows from used in operations before changes in working capital for the quarter ending 2023-06-30 was -$37.51M.
- ADC Therapeutics SA cash flows from used in operations before changes in working capital for the quarter ending 2023-03-31 was -$42.28M.
- ADC Therapeutics SA cash flows from used in operations before changes in working capital for the quarter ending 2022-12-31 was $379.00K.
| Period end | Cash Flows From Used In Operations Before Changes In Working Capital 3 month | Cash Flows From Used In Operations Before Changes In Working Capital 3 month as first filed | Cash Flows From Used In Operations Before Changes In Working Capital 6 month | Cash Flows From Used In Operations Before Changes In Working Capital 6 month as first filed | Cash Flows From Used In Operations Before Changes In Working Capital 9 month | Cash Flows From Used In Operations Before Changes In Working Capital 9 month as first filed | Cash Flows From Used In Operations Before Changes In Working Capital 12 month | Cash Flows From Used In Operations Before Changes In Working Capital 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | -$33.50M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$71.01M derived: sum of 2 quarters · filed 2023-11-07 | -$113.28M 6-K · filed 2023-11-07 | -$112.91M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2023-06-30 | -$37.51M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$79.79M 6-K · filed 2023-08-08 | -$79.41M derived: sum of 3 quarters · filed 2023-08-08 | -$65.74M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2023-03-31 | -$42.28M 6-K · filed 2023-05-09 | -$41.90M derived: sum of 2 quarters · filed 2023-05-09 | -$28.23M derived: sum of 3 quarters · filed 2023-11-07 | -$83.99M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-12-31 | $379.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $14.05M derived: sum of 2 quarters · filed 2023-11-07 | -$41.71M derived: sum of 3 quarters · filed 2023-11-07 | -$71.08M 20-F · filed 2023-03-15 | ||||
| 2022-09-30 | $13.67M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$42.09M derived: sum of 2 quarters · filed 2023-11-07 | -$71.46M 6-K · filed 2023-11-07 | -$125.59M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$55.76M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$85.13M 6-K · filed 2023-08-08 | -$139.26M derived: sum of 3 quarters · filed 2023-08-08 | -$182.30M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | -$29.37M 6-K · filed 2023-05-09 | -$83.50M derived: sum of 2 quarters · filed 2023-05-09 | -$126.54M derived: sum of 3 quarters · filed 2023-05-09 | -$185.19M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | -$54.13M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$97.17M derived: sum of 2 quarters · filed 2023-03-15 | -$155.82M derived: sum of 3 quarters · filed 2023-03-15 | -$211.78M 20-F · filed 2023-03-15 | -$207.22M 20-F · filed 2022-03-17 | |||
| 2021-09-30 | -$43.03M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | -$101.69M derived: sum of 2 quarters · filed 2022-11-08 | -$157.65M 6-K · filed 2022-11-08 | -$157.16M 6-K · filed 2021-11-02 | -$219.51M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-06-30 | -$58.65M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | -$114.62M 6-K · filed 2022-08-09 | -$114.27M 6-K · filed 2021-08-03 | -$176.47M derived: sum of 3 quarters · filed 2023-03-15 | -$217.33M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-03-31 | -$55.97M 6-K · filed 2022-05-09 | -$55.86M 6-K · filed 2021-05-06 | -$117.82M derived: sum of 2 quarters · filed 2023-03-15 | -$158.68M derived: sum of 3 quarters · filed 2023-03-15 | -$197.28M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2020-12-31 | -$61.85M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$102.72M derived: sum of 2 quarters · filed 2023-03-15 | -$141.31M derived: sum of 3 quarters · filed 2023-03-15 | -$180.73M 20-F · filed 2023-03-15 | -$180.41M 20-F · filed 2021-03-18 | |||
| 2020-09-30 | -$40.86M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | -$79.46M derived: sum of 2 quarters · filed 2021-11-02 | -$118.88M 6-K · filed 2021-11-02 | |||||
| 2020-06-30 | -$38.60M derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | -$78.02M 6-K · filed 2021-08-03 | ||||||
| 2020-03-31 | -$39.42M 6-K · filed 2021-05-06 | |||||||
| 2019-12-31 | -$114.75M 20-F · filed 2022-03-17 | |||||||
| 2018-12-31 | -$123.42M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |